Shukra Pharmaceuticals Limited

NSE: SHUKRAPHAR

29

total announcements

SHUKRAPHAR.NS · 15 min delayed

Key Stats · Yahoo Finance · as of 19 Nov 2026

Market Cap

₹3,638 Cr

P/E (TTM)

81.4

EPS (TTM)

₹1.01

52W Low

₹40.06

52W High

₹84.80

Dividend Yield

0.01%

Beta

0.55

Price / Book

30.4

Return on Equity

48.08%

Debt / Equity

19.0

Revenue (TTM)

₹111 Cr

Gross Margin

75.31%

Operating Margin

57.88%

NSEOutcome of Board MeetingFundraise2 Sept 2026

Shukra Pharmaceuticals Limited

Outcome of Board Meeting

Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 02, 2026, where the Board of Directors approved allotment of 11,73,000 fully paid-up equity shares to Navkar Surgical Gujarat Limited, warrant holders (Promoter), upon conversion of warrants into equity shares.

Read more →📎 1 attachment
NSECopy of Newspaper Publication31 Aug 2026

Shukra Pharmaceuticals Limited

Copy of Newspaper Publication

Shukra Pharmaceuticals Limited has informed the Exchange about the completion of dispatch of the postal Ballot Notice as published in Business Standard (English) and in Jai Hind (Gujarati) on August 31, 2026.

Read more →📎 1 attachment
NSEShareholders meetingshareholders_meeting27 Aug 2026

Shukra Pharmaceuticals Limited

Shareholders meeting

Shukra Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot for approval of special businesses through e-voting process.

Read more →📎 1 attachment
NSEOutcome of Board MeetingM&A22 Aug 2026

Shukra Pharmaceuticals Limited

Outcome of Board Meeting

Shukra Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 22, 2026. The Board of Directors considered and approved several items, including the change of the company's name from 'Shukra Pharmaceuticals Limited' to 'Shukra Medtech Limited', alteration in the main objects of the Company, and consequential alteration in the Main Object Clause of the Memorandum of Association. The company also approved the draft notice of Postal Ballot to obtain shareholders' approval for the aforesaid relevant agenda items and appointed CS Rupal Patel as a Scrutinizer to scrutinize the e-voting process.

Read more →📎 1 attachment
NSEGeneral UpdatesRegulatory17 Aug 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has informed the Exchange about General Updates regarding media coverage of its NSE listing and strategic direction.

Read more →📎 1 attachment
NSEGeneral Updates▲ PositiveExpansion14 Aug 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, including approval of proposal for change of name and expansion of main objects to include medical technology.

Read more →📎 1 attachment
NSEGeneral Updates14 Aug 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has informed the Exchange about General Updates

NSEGeneral UpdatesExpansion14 Aug 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has informed the Exchange about General Updates, specifically the commencement of trading of its equity shares on the National Stock Exchange of India Limited (NSE) with effect from August 14, 2026.

Read more →📎 1 attachment
NSEGeneral Updates▲ PositiveExpansion14 Aug 2026

Shukra Pharmaceuticals Limited

General Updates

Shukra Pharmaceuticals Limited has announced its direct listing on the National Stock Exchange (NSE) and will commence trading on August 14, 2026. The company will continue to trade on the Bombay Stock Exchange (BSE) as well. The listing is aimed at expanding the company's visibility, attracting a broader base of institutional and retail investors, and deepening market liquidity.

Read more →📎 1 attachment
← PreviousPage 2 of 2